Loading
Some cancer-driving proteins gather into droplet-like blobs inside the nucleus to switch genes on. Drugs that dissolve those blobs might switch the cancer programme off.
Transcriptional condensates concentrate MYC, fusion oncoproteins, mediator complex and RNA polymerase at super-enhancers. Certain drugs, including some antineoplastics, concentrate selectively in condensates, and condensate-modulating chemotypes have been reported. A dedicated screen using condensate-specific reporters (optoDroplet or in vitro reconstitution with labelled scaffolds) could identify compounds that selectively dissolve oncogenic condensates while sparing normal ones.
Shares Drugging the 'undruggable' cancer targets, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, Broad Institute of MIT and Harvard, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Broad Institute of MIT and Harvard, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, Broad Institute of MIT and Harvard, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Broad Institute of MIT and Harvard, The undruggable drivers.